Does trofinetide treatment show symptom improvement for children with Rett syndrome?

Trofinetide is the first FDA-approved medication for Rett syndrome, a rare genetic disorder that causes developmental regression. Clinical trials and real-world studies confirm that the drug helps reduce core symptoms like hand stereotypies and breathing irregularities. A 2024 observational study found that 75.9% of individuals experienced some improvement in symptoms such as engagement, communication, and motor skills over 12 months ⁴.

What the research says

In a large randomized phase 3 trial, trofinetide significantly improved behavioral scores compared to placebo. The Rett Syndrome Behaviour Questionnaire scores improved by an average of 4.9 points versus 1.7 points for placebo ⁵. Communication skills also showed significant gains, with the Social Composite score improving by 0.1 points versus a decline of 1.1 points in the placebo group ⁵.

Long-term data from a 40-week extension study supports these findings. Participants on trofinetide continued to show improvement in behavioral scores, with a mean improvement of 7.3 points from the original trial baseline ⁷. This suggests the drug provides sustained benefit over time for many patients.

Real-world effectiveness mirrors these trial results. An observational study of 55 individuals found that side effects were often better managed in practice than in earlier trials, with only 48.1% reporting diarrhea ⁴. This real-world data highlights the importance of careful dosing and side effect management to help patients stay on the medication longer ⁴.

What to ask your doctor

• How should we manage diarrhea and vomiting if they occur while taking trofinetide?
• What is the best way to titrate the dose to minimize side effects?
• Are there any specific signs of improvement I should watch for in my child?
• How often should we reassess behavior and communication skills to track progress?